Pfizer Claims No Link To Generic-Drug Price-Fix Plot

Law360 (December 2, 2019, 4:05 PM EST) -- Pfizer Inc. is seeking to exit the sweeping Pennsylvania multidistrict litigation alleging it conspired with other major drugmakers to keep generic prices high, as the branded drugmaker said its only ties to the allegations stem from a subsidiary, and that's not enough.

A coalition of states, led by Connecticut, contend that Pfizer was one of many industry heavyweights that coordinated price increases for generic drugs running the pharmaceutical gamut, including treatments for basic infections, diabetes, cancer, epilepsy, multiple sclerosis, HIV and ADHD, plus antidepressants, contraceptives and anti-inflammatory medications.

However, Pfizer argued in a dismissal bid Friday that as a branded drugmaker,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS